Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. - Wikidata - awgldk - TriplyDB

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.

http://www.wikidata.org/entity/Q34042430

about

Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors Clinical application of adoptive T cell therapy in solid tumors Advantages and applications of CAR-expressing natural killer cells Utilizing chimeric antigen receptors to direct natural killer cell activity Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity CAR-modified T-cell therapy for cancer: an updated review.Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy.In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Natural killer cells in inflammatory heart disease.Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody.Engineering Natural Killer Cells for Cancer Immunotherapy.Are natural killer cells superior CAR drivers?Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.

P2860

Q26795540-FA797A84-3A90-4E03-99A2-FE225349F17D Q27011283-9FF9DDFC-2ECB-4813-8DA7-CD6887F00F9B Q28080875-970D8CA0-56FC-4831-9F3D-D84EF13245F7 Q28082868-04F04AD8-4C54-4192-AD9B-30CD32AF471A Q33700795-04F44E7B-94A6-415B-BD72-0CB5EEB664FB Q34044213-22DC6121-BFEC-4116-8C7C-B7E9D7240579 Q34248531-1096807C-41DE-4327-A081-600D0603E682 Q35634680-E0834DD7-E747-4EEA-A418-BE000AB1AF45 Q35971763-C4CF4979-6FFC-4234-A192-09AEF2DDACE5 Q36333154-4F09668F-489D-4222-AE73-9002BA5C934B Q36470354-390E1C84-EAB2-476A-8D34-C3F7D9F4812A Q37434670-03DF6CEC-B2B2-4B65-B0FC-E0CD930635D0 Q37488222-2DA62A4D-EA7E-4BE8-971B-AF993898C1B3 Q38525034-9C8272A6-F5F2-4BCB-B80E-FE24088CCCEA Q38666579-89F00981-CBCF-4822-BC63-983B7593214D Q38783833-96509300-DF25-468D-AB2F-416D399F7CCA Q39022829-1B1AA7D5-664D-4C43-90B9-1031DB16ABEE Q39037600-6A9D0F66-0217-441E-8AAD-C45DA4534ED2 Q39085019-E94A8892-0E06-4F76-8E96-67CFEDF7F2CD Q39408704-F48DB085-781B-4AC1-A149-D4D4235519DD Q42952399-54529C6B-4C1C-4677-AD52-CACD7F586B2A Q49290997-FB938B0C-12BA-4072-A67C-1BEBE0C44DC4 Q52691571-4AA11919-7E55-4929-86F2-CADC3E319A8F Q52804817-49605A85-E953-40D2-A32D-089AD9B29CB6 Q53705286-A41A9382-F0ED-48E9-8639-3E2E3029AB7C

P2860

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.

http://www.wikidata.org/entity/Q34042430

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@ast

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@en

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@nl

type

label

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@ast

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@en

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@nl

prefLabel

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@ast

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@en

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@nl

P1433

Q34042430-8E1A7198-58DC-40CD-92EE-09616E95B80D

P1476

Q34042430-A005B48C-88FB-4AFC-90FB-E1F3BDA1157C

P2093

Q34042430-42651D2F-81AA-4B31-B049-93F070BA63BF

Q34042430-6D36402B-9E8F-437B-BE52-800DBFFB0011

Q34042430-ABEE43A3-060E-4FBD-8E02-7CBEF48CD733

P2860

Q34042430-0E5B117E-A10A-4164-96EB-E77B5A094A77

Q34042430-10D366A4-A089-4910-8838-3BC4D225FDCB

Q34042430-116B124E-20BE-4E83-80F7-304035EC60CE

Q34042430-117377D6-7C98-4951-8B80-E443939CF7E1

Q34042430-13F40ED0-23FA-44F0-AD33-A5B442F3E98A

Q34042430-1FF49A22-76A4-411D-A21D-B1EE38E08E8B

Q34042430-207954D0-744F-477E-AA98-DBA9D8BA001D

Q34042430-208713AF-D67A-4020-BC48-3B6B637300DF

Q34042430-2753DD74-4078-4175-855F-98915E6EF31A

Q34042430-28268C6C-8806-40A0-B6EB-58080484C334

P2888

Q34042430-EF62EB47-D27F-4107-9A11-3448891BD509

P304

Q34042430-7AF6B1D5-526D-4689-AF7D-B74C6BE68E9F

P31

Q34042430-D4F3ED20-7EE1-4B77-B317-30189313984B

P356

Q34042430-A1CAB288-AE92-42FE-AC56-584F142A349E

P433

Q34042430-F2112B48-F8E0-4A8E-962C-6AAF42BD6619

P478

Q34042430-22BC86AA-4521-4780-A46F-83DAE54D4A24

P577

Q34042430-B9E5A45E-F40E-42C2-B855-AA3DFB599773

P6179

Q34042430-C041ADC5-CD39-4388-9BCF-22E28726C302

P698

Q34042430-5CB0E498-7B3C-4CED-91A7-219D4C41E875

P356

P1433

Cancer Gene Therapy

P1476

Retargeting NK92 cells using a ...... fic chimeric antigen receptor.

@en

P2093

D V Tassev

http://www.w3.org/2001/XMLSchema#string

M Cheng

http://www.w3.org/2001/XMLSchema#string

N-K V Cheung

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

Structure of the complex between human T-cell receptor, viral peptide and HLA-A2

Phenotypic analysis of antigen-specific T lymphocytes

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Antibody arrays for high-throughput screening of antibody-antigen interactions.

TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity.

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.

Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.

Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts.

Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.

P2888

P304

84-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CGT.2011.66

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042612902

http://www.w3.org/2001/XMLSchema#string

P698

21979579

http://www.w3.org/2001/XMLSchema#string